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ORIGINAL ARTICLE INFECTIOUS DISEASESIdentiﬁcation of patients at high risk for Clostridium difﬁcile infection:
development and validation of a risk prediction model in hospitalized
patients treated with antibioticsC. H. van Werkhoven1, J. van der Tempel2, R. Jajou5, S. F. T. Thijsen4, R. J. A. Diepersloot4, M. J. M. Bonten1,3, D. F. Postma1 and
J. J. Oosterheert2
1) Julius Center for Health Sciences and Primary Care, 2) Department of Internal Medicine and Infectious Diseases, 3) Department of Medical Microbiology,
University Medical Center, 4) Department of Medical Microbiology and Immunology, Diakonessenhuis, Utrecht and 5) Health Sciences, VU University Amsterdam,
The NetherlandsAbstractTo develop and validate a prediction model for Clostridium difﬁcile infection (CDI) in hospitalized patients treated with systemic antibiotics, we
performed a case–cohort study in a tertiary (derivation) and secondary care hospital (validation). Cases had a positive Clostridium test and
were treated with systemic antibiotics before suspicion of CDI. Controls were randomly selected from hospitalized patients treated with
systemic antibiotics. Potential predictors were selected from the literature. Logistic regression was used to derive the model.
Discrimination and calibration of the model were tested in internal and external validation. A total of 180 cases and 330 controls were
included for derivation. Age >65 years, recent hospitalization, CDI history, malignancy, chronic renal failure, use of immunosuppressants,
receipt of antibiotics before admission, nonsurgical admission, admission to the intensive care unit, gastric tube feeding, treatment with
cephalosporins and presence of an underlying infection were independent predictors of CDI. The area under the receiver operating
characteristic curve of the model in the derivation cohort was 0.84 (95% conﬁdence interval 0.80–0.87), and was reduced to 0.81 after
internal validation. In external validation, consisting of 97 cases and 417 controls, the model area under the curve was 0.81 (95%
conﬁdence interval 0.77–0.85) and model calibration was adequate (Brier score 0.004). A simpliﬁed risk score was derived. Using a
cutoff of 7 points, the positive predictive value, sensitivity and speciﬁcity were 1.0%, 72% and 73%, respectively. In conclusion, a risk
prediction model was developed and validated, with good discrimination and calibration, that can be used to target preventive
interventions in patients with increased risk of CDI.
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p://dx.doi.org/10.1016/j.cmi.2015.04.005IntroductionClostridium difﬁcile infection (CDI) is an important cause of
antibiotic-associated diarrhoea and infectious colitis. CDI has
shown increasing incidence and mortality rates worldwide since
the 1990s [1,2] and is associated with increased healthcare
costs [1,3,4]. Disruption of the intestinal bacterial ﬂora by
antibiotics is recognized as the most important pathogenic
mechanism and risk factor of CDI [5–8].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI van Werkhoven et al. Predicting the risk of C. difﬁcile infection 786.e2Antibiotic stewardship programs, probiotics and infection
control policies focussing on prevention of spread seem to be
able to reduce CDI incidence [9–14]. However, applying these
interventions to all hospitalized patients may not be cost-
effective in all settings. For example, in hospitals with a low
incidence of CDI, the number needed to treat (NNT) to pre-
vent one case of CDI might be unfavourably high. In that case, if
possible, preventive interventions could be targeted to those at
highest risk of CDI, thereby reducing the NNT.
Despite good discriminative power in previously reported
risk prediction models [15–17], none of these can be easily
implemented in clinical practice because variables were
included that are not generally measured, such as nutritional
status, or that are unknown when prediction is warranted, such
as total length of intensive care unit (ICU) stay. Moreover, two
of these studies included all hospitalized patients, regardless of
receipt of antibiotics. Because systemic antibiotic treatment is
the most important pathogenesis for CDI, we developed and
validated a model to identify patients at the highest risk of CDI
who had received at least one dose of systemic antibiotics
during their hospitalization.MethodsDesign and setting
For derivation of the model, we performed a retrospective
case–cohort study at the University Medical Center Utrecht, a
1042-bed tertiary care hospital in the Netherlands, with about
28 000 clinical hospitalizations annually. We included patients
who were admitted between January 2005 and December
2011. No outbreaks of CDI were experienced in this hospital
during the study period. External validation of the derived
model was performed in the Diakonessenhuis hospital in pa-
tients admitted between November 2010 and May 2013, using
the same retrospective design and the same inclusion and
exclusion criteria. This study period was chosen because data
on antibiotic use before November 2010 were not electroni-
cally available. The Diakonessenhuis hospital is a 451-bed sec-
ondary care teaching hospital, with about 26 000 clinical
hospitalizations annually. From January to June 2011 the Dia-
konessenhuis hospital experienced an outbreak of C. difﬁcile.
During this period, the incidence of CDI was increased three-
fold compared to the previous 3 years. Most CDI episodes
occurred in one of the internal departments, the pulmonology
department and the geriatric department, and three were found
in the ICU. The outbreak was managed using isolation mea-
sures, intensiﬁed cleaning of paramedical devices and of affected
rooms, and an antibiotic stewardship program, restricting use
of cephalosporins, clindamycin and ﬂuoroquinolones, for theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Ininvolved departments. Both hospitals provide a broad range of
medical and surgical services.
Selection of cases and controls
Inclusion criteria were age over 16 years, hospitalization for at
least 48 hours and receipt of systemic antibiotic therapy during
hospitalization. Patients were excluded when only low-dose
erythromycin was prescribed as prokinetic therapy because
this is not associated with CDI [18], or when suspicion of CDI
was present before initiation of in-hospital antibiotic treatment
because in these patients prediction is no longer warranted.
However, when patients were admitted for CDI within 28 days
of a previous admission, the previous admission was considered
for inclusion. In the derivation cohort, patients with multiple
episodes of CDI were only included for the ﬁrst eligible
admission to prevent overestimation of effect estimates due to
similarity of predictors within episodes of one patient.
Cases were selected based on the detection of C. difﬁcile in
clinical stool samples. As a result of differences in local testing
practices, cases for the derivation cohort were selected on the
basis of a positive C. difﬁcile toxin assay (ImmunoCard, toxins A
and B), whereas in the validation cohort CDI was deﬁned as a
positive C. difﬁcile toxin assay (ImmunoCard; dubious test re-
sults were conﬁrmed by the GeneXpert PCR test), a positive
PCR result, or C. difﬁcile cultured from stool samples. The
clinical indication for testing was suspicion of infectious diar-
rhoea associated with antibiotic use in both hospitals. In the
validation cohort, the toxin assay was the standard test, and
upon receipt of negative results with sustained suspicion of
CDI, PCR was performed. Screening procedures were not in
place at either hospital. During the outbreak period in the
validation cohort, testing was performed in case of diarrhoea,
irrespective of association with antibiotics.
For the derivation cohort, we aimed for a case–control ratio
of 1:2, and controls were randomly selected from the Utrecht
Patient Oriented Database, an infrastructure of relational da-
tabases containing clinical and administrative data for all patients
treated at the University Medical Center Utrecht, in accor-
dance with current regulations concerning privacy and ethics as
described elsewhere [19]. First, admission and pharmacy data
were merged to only select admissions in which systemic an-
tibiotics were provided. Next, controls were randomly selected
from this data set. Patients with multiple admissions had a
higher probability of being selected; however, selection of
multiple admissions of a single patient was prohibited because
most parameters are expected to be the same in the different
episodes and this may cause overestimation of the odds ratios.
For the validation cohort, we aimed for a case–control ratio
of 1:4, which was chosen to increase precision, given the lower
number of cases in the validation cohort. Controls werefectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 786.e1–786.e8
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biotic therapy during the study period, using the hospital
admission and pharmacy registries. Selection of multiple ad-
missions of the same patient was allowed in the validation
cohort in order to allow model validation in a real-life situation.
Data collection
Clinical data were manually extracted from the electronic pa-
tient records. For the purpose of prediction, only data that
were available on or before the ﬁrst day of in-hospital antibiotic
therapy were recorded. In the derivation sample, the severity of
comorbidities was classiﬁed using an adapted McCabe– Jackson
comorbidity severity index [20], limited to three categories: no
comorbidity, nonfatal comorbidities and fatal comorbidities.
Exposure to CDI was pragmatically deﬁned as positive if up to 2
weeks before the patient’s antibiotics start date, a CDI-positive
patient had been present at the same hospital ward. This deﬁ-
nition was chosen because the prediction model has to be us-
able in clinical practice, taking into account that more
misclassiﬁcations are expected for episodes that occurred more
than 2 weeks ago. Antibiotic use before admission was deﬁned
as any systemic antibiotic use in the 14 days prior to the current
admission. This time period was chosen because antibiotic use
more than 2 weeks before admission is generally poorly
documented, and because these data are routinely collected by
the clinician, making it easier to apply the model in clinical
practice.
Permission for the study was obtained from the ethics re-
view board of both hospitals, and a waiver for informed consent
was granted.
Statistical analysis
Multiple logistic regression was performed, starting with all
potential predictors. Stepwise backward elimination was used to
determine the best predictive model, excluding variables with a
p value of >0.05 using the likelihood ratio test. Internal validation
of the model was performed using bootstrapping techniques,
and bias-corrected estimates of the regression coefﬁcients were
derived by multiplying the original coefﬁcients with the slope of
the calibration curve. Discriminative capacity of the model in the
derivation and validation cohort was assessed using the area
under the receiver operating characteristic curve (AUC). Ab-
solute predicted probabilities were corrected for the case–
control ratio and sampling fraction, as described elsewhere [21].
Calibration of the model was tested by plotting the predicted
probability vs. the observed outcome. A risk score was derived
from the regression coefﬁcients, multiplied by 2 and subse-
quently rounded. Sensitivity, speciﬁcity and positive and negative
predictive values were estimated for different risk levels. Sub-
group analysis was performed among patients during theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectoutbreak period in the validation cohort. Analysis was per-
formed in R software (version 2.15.2), including packages rms
(version 3.6.3) and pROC (version 1.5.4) [22].ResultsPatients
Characteristics of the study populations are listed in Table 1.
Compared to controls, CDI patients were generally older, had
more comorbidities, had received more antibiotics before
admission and more frequently received immunosuppressants
and gastric acid suppressants.
Model derivation
In the derivation study, 180 CDI patients and 319 controls
were included. CDI developed during hospitalization in 146
cases and within 28 days of discharge in 34 cases. Reasons for
exclusion of patients are summarized in Fig. 1. During the study
period, the incidence of CDI was 5.2 (95% conﬁdence interval
(CI) 4.5–5.9) per 1000 admissions in patients receiving systemic
antibiotic therapy.
Variables in the ﬁnal model, including bias-corrected esti-
mates, are presented in Table 2. Both the model and the risk
score showed good discrimination, with AUC values of 0.84
(95% conﬁdence interval (CI) 0.80–0.87) and 0.83 (95% CI
0.80–0.87), respectively (Fig. 2). The bias-corrected AUC, after
internal validation, was 0.81.
Model validation
In the validation study, 97 CDI patients and 419 controls were
included. CDI developed during hospitalization in 77 cases and
within 28 days of discharge in 20 cases. Of the patients, 95 were
identiﬁed by a positive toxin assay and two were PCR positive
only. Reasons for exclusion of patients are summarized in Fig. 1.
During the study period, the incidence of CDI was 4.0 (95% CI
3.2–4.8) per 1000 admissions in patients receiving systemic
antibiotic therapy. During and outside the outbreak period, the
incidence was 8.8 (95% CI 6.2–11.6) and 2.8 (95% CI 2.1–3.6)
per 1000 admissions, respectively.
The AUC of the model and risk score were 0.81 (95% CI
0.77–0.85) and 0.81 (95% CI 0.77–0.86), respectively (Fig. 2).
The predicted risk was generally well calibrated with the
observed outcome, with a Brier score of 0.004 (a Brier score of
0 represents perfect calibration). For those with the highest
risk, the predicted risk was somewhat underestimated (Fig. 2).
This group consisted of two controls, which represented less
than 1% of the base population.
Positive predictive values, sensitivities and speciﬁcities of the
risk score in the validation cohort are presented in Table 3.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 786.e1–786.e8
FIG. 1. Inclusion ﬂowcharts of cases and controls for derivation and validation studies.
TABLE 1. Population characteristics
Characteristic
Derivation cohort Validation cohort
CDI cases (n [ 180) Controls (n [ 319) CDI cases (n [ 97) Controls (n [ 419)
Male gender 102 (56.7%) 182 (57.1%) 46 (47.4%) 169 (40.3%)
Age (years) 66 (54–76) 61 (48–71) 77 (68–85) 71 (60–81)
Medical history
Previous (<90 days) hospitalization 76 (42.2%) 72 (22.6%) 50 (51.5%) 55 (13.1%)
Cardiovascular disease 44 (24.4%) 102 (32.0%) 40 (41.2%) 88 (21.0%)
Malignancy 49 (27.2%) 53 (16.6%) 19 (19.6%) 61 (14.6%)
Diabetes mellitus 24 (13.3%) 40 (12.5%) 11 (11.3%) 73 (17.4%)
Chronic renal failure 31 (17.2%) 15 (4.7%) 2 (2.1%) 3 (0.7%)
Inﬂammatory bowel disease 3 (1.7%) 7 (2.2%) 3 (3.1%) 6 (1.4%)
History of CDI 5 (2.8%)a 1 (0.3%) 2 (2.1%) 0
Medication use
Immunosuppressants (past 90 days) 60 (33.3%) 44 (13.8%) 11 (11.3%) 18 (4.3%)
Gastric acids suppressants (past 14 days) 82 (45.6%) 122 (38.2%) 58 (59.8%) 133 (31.7%)
Antibiotics before hospitalization (14 days) 61 (33.9%) 40 (12.5%) 37 (38.1%) 67 (16.0%)
Admission
Surgical admission 53 (29.4%) 204 (63.9%) 22 (22.7%) 224 (53.5%)
Total length of stay 26.5 (14–67.3) 8 (5–16) 22 (10–32) 6 (4–11)
Length of stay until ﬁrst Clostridium difﬁcile test positive 18.5 (9–34) NA 9 (3–18) NA
ICU admissionb 28 (15.6%) 23 (7.2%) 18 (18.6%) 19 (4.5%)
Tube feedingb 20 (11.1%) 7 (2.2%) 7 (7.2%) 4 (1.0%)
CDI exposure at time of prediction 24 (13.3%) 19 (6.0%) NA NA
Initial antibiotic treatment
β-Lactams 39 (21.7%) 85 (26.6%) 26 (26.8%) 117 (27.9%)
Cephalosporins 102 (56.7) 172 (53.9) 60 (61.9%) 238 (56.8%)
Macrolides 8 (4.4%) 26 (8.2%) 13 (13.4%) 26 (6.2%)
Quinolones 24 (13.3%) 35 (11.0%) 7 (7.2%) 23 (5.5%)
Carbapenems 13 (7.2%) 4 (1.3%) 0 4 (1.0%)
Other antibiotics 48 (26.7%) 71 (22.3%) 12 (12.4%) 70 (16.7%)
Indication for antibiotics
Underlying infection 132 (73.3%) 120 (37.6%) 86 (88.7%) 274 (65.4%)
Respiratory tract infection 53 (29.4%) 39 (12.2%) 39 (40.2%) 87 (20.8%)
Urinary tract infection 30 (16.7%) 23 (7.2%) 14 (14.4%) 71 (16.9%)
Other infections 49 (27.2%) 58 (18.2%) 36 (37.1%) 120 (28.6%)
Prophylactic treatment 48 (26.7%) 199 (62.4%) 11 (11.3%) 145 (34.6%)
Data are presented as n (%) or median (interquartile range).
CDI, Clostridium difﬁcile infection; ICU, intensive care unit; NA, not applicable.
aFor CDI cases in the derivation cohort, these include CDI episodes that had occurred before 2005, in another hospital or in a noneligible previous admission.
bUntil initiation of antibiotic treatment.
CMI van Werkhoven et al. Predicting the risk of C. difﬁcile infection 786.e4Sensitivity analyses
For patients with the ﬁrst in-hospital antibiotic dose within the
outbreak period, the model had an AUC of 0.86 (95% CI
0.79–0.92), vs. 0.80 (95% CI 0.74–0.86) outside the outbreak
period (p 0.20). Calibration of the model during the outbreakClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inperiod showed an underestimation of the predicted probability
in the high risk patients (Brier score 0.009).
Additionally, a sensitivity analysis was performed using a more
liberal p value of 0.2 to select predictors because it has been
debated whether higher p values lead to more generalizablefectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 786.e1–786.e8
TABLE 2. Parameters in the ﬁnal model
Predictora
Model parameters Bias correctedb
Risk scoreBeta OR (95% CI) Beta OR (95% CI)
Age >65 years 0.568 1.77 (1.11–2.80) 0.456 1.58 (0.99–2.51) 1
Previous hospitalization1 0.536 1.71 (1.04–2.81) 0.430 1.54 (0.94–2.53) 1
History of CDI 3.510 33.6 (2.82–397.3) 2.819 16.8 (1.41–198.8) 7
Malignancy2 0.574 1.78 (1.01–3.12) 0.461 1.59 (0.90–2.79) 1
Chronic renal failure3 1.104 3.02 (1.43–6.38) 0.887 2.43 (1.15–5.13) 2
Use of immunosuppressants4 0.764 2.15 (1.24–3.71) 0.613 1.85 (1.07–3.19) 2
Antibiotics before admission5 1.040 2.83 (1.62–4.96) 0.835 2.31 (1.32–4.03) 2
Receipt of cephalosporins 0.896 2.45 (1.49–4.02) 0.719 2.05 (1.25–3.37) 2
Underlying infection6 1.020 2.77 (1.65–4.66) 0.819 2.27 (1.35–3.81) 2
Nonsurgical admission 0.998 2.71 (1.59–4.64) 0.801 2.23 (1.30–3.81) 2
ICU admission 0.894 2.45 (1.20–5.00) 0.718 2.05 (1.00–4.18) 2
Tube feeding 1.403 4.07 (1.46–11.31) 1.127 3.09 (1.11–8.59) 3
OR, odds ratio; CI, conﬁdence interval; CDI, Clostridium difﬁcile infection; ICU, intensive care unit.
aPredictor values were recorded as available on the ﬁrst day of in-hospital antibiotic administration. Deﬁnitions of predictors are as follows: 1) within the last 90 days before current
admission; 2) any malignancy requiring chemotherapy or radiotherapy in the past 5 years; 3) with indication for dialysis or renal transplantation; 4) within the past 90 days; 5) with in
the past 14 days before admission; and 6) receiving antibiotics for an infection, as opposed to receiving prophylactic antibiotic treatment. Variables not in the model include severity
of comorbidities, CDI exposure, use of gastric acid suppressants within the past 14 days, classes of in-hospital antibiotic treatment (β-lactams, macrolides, quinolones, carbapenems
and others).
bAfter internal validation, the regression coefﬁcients (beta) were multiplied by 0.803 to arrive at the bias-corrected effect estimates.
FIG. 2. Performance. (a) ROC curve of simpliﬁed risk score in derivation and validation cohort. (b) Calibration of predicted and observed probability
of CDI in external validation, zoomed in to show 99.5% of the data. ROC, receiver operating characteristic; AUC, area under the ROC curve.
TABLE 3. Model performance at different cutoff points using simpliﬁed risk score
Score
Total study period Outbreak period
Positive (%)a PPV (%) NPV (%) Sensitivity (%) Speciﬁcity (%) Positive (%)a PPV (%) NPV (%) Sensitivity (%) Speciﬁcity (%)
3 88 0.5 100 100 12 90 1.0 100 100 10
4 63 0.6 100 97 37 62 1.4 100 100 39
5 51 0.7 99.9 93 49 53 1.6 99.9 95 47
6 36 0.9 99.9 85 64 33 2.4 99.9 90 67
7 27 1.0 99.8 72 73 22 2.9 99.7 73 79
8 14 1.5 99.8 52 86 9 4.8 99.5 49 91
9 7 2.0 99.7 36 93 3 9.6 99.4 34 97
10 4 2.7 99.7 27 96 0 100 99.3 24 100
Each row that represents NPV, PPV, sensitivity and speciﬁcity when a score equalled or exceeded the cutoff point is considered high risk.
PPV, positive predictive value; NPV, negative predictive value.
aPercentage of patients with risk score above the cutoff point.
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CMI van Werkhoven et al. Predicting the risk of C. difﬁcile infection 786.e6models [23]. In this analysis, receipt of carbapenems remained in
the model after stepwise elimination. However, overall model
performance did not improve, both in the derivation and in the
validation cohort.DiscussionWe developed and validated a model to predict the risk of CDI
in hospitalized patients treated with systemic antibiotics. Both
the model and the simpliﬁed risk score showed good discrim-
ination, illustrated by an AUC of 0.81 in internal and external
validation. Discrimination of the simpliﬁed risk score was
similar to the full model in all settings. The parameters in the
model are plausible, given the epidemiology of C. difﬁcile. This
model can be used to target risk-reducing interventions to
patients at high risk of CDI. For example, if all patients in our
validation cohort would undergo the restrictive antibiotic
stewardship program, with an efﬁcacy of 54% to prevent CDI
[10], the NNT to prevent one CDI case would be 463 (the
inverse of CDI incidence divided by the efﬁcacy). By limiting the
intervention to patients with a risk score of 7 or higher,
assuming the same efﬁcacy of the intervention, the NNT would
decrease to 185 (the inverse of the positive predictive value
divided by the reduction percentage). With this approach, up to
39% of the CDI cases could still be prevented by the inter-
vention (sensitivity times efﬁcacy), while the intervention would
be restricted to only 27% of the patients (number of patients
scoring positive; Table 3). Depending on the costs and disad-
vantages of the intervention, this could be a more acceptable
approach than treating the whole population.
The incidence of CDI in our study population was low
compared to some other countries, with incidences up to 10
per 1000 admissions in all hospitalized patients [15], and the
previously published incidence in the derivation hospital was
relatively low compared to other Dutch hospitals (on





surveillance). During the study periods, incidence in the
derivation cohort was approximately 11 per 10 000 admis-
sions (independent of antibiotic use), with minor ﬂuctuations;
in the validation cohort, this was approximately 15 per
10 000 admissions, varying from 11 outside the outbreak
period to 32 during the outbreak period (data not shown). As
a result of these low incidences, the positive predictive
values, even in the group with high risk scores, remained low.
In patients receiving systemic antibiotics, incidence wasClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inhigher in the derivation study compared to the validation
study, presumably because the derivation study took place in
a tertiary care hospital.
The outbreak of C. difﬁcile in the Diakonessenhuis hospital
may have inﬂuenced the results of the validation. However,
discrimination of the model was similar during the outbreak
period compared to the nonoutbreak setting. This suggests that
although the model has been developed in a low-incidence
setting, it is generalizable to a setting with higher incidence. It
should be noted that the incidence during the outbreak period
was still relatively low. Therefore, generalizability of the model
to high incidence settings should be assessed before imple-
mentation of the model in clinical practice.
CDI exposure did not improve model performance in our
study. This may be due to the pragmatic and (consequently)
imprecise deﬁnition of CDI exposure, or to the low incidence
of CDI in the derivation study. A previously proposed sensitive
method to measure CDI exposure uses admission data and CDI
test results in a computerized model [15]. However, this re-
quires adaptation of the model to the infrastructure of every
individual hospital and limits applicability of the model to hos-
pitals where these data are electronically available. Moreover,
differences in testing and isolation strategies and of patient
migration patterns will limit the generalizability of CDI expo-
sure effects. It has also been suggested that infection pressure
partly represents the physician’s alertness instead of real
infection pressure [25].
Colonization with C. difﬁcile at admission has been suggested
as a risk factor for CDI [26]. Currently no routine screening is
performed; therefore, as a result of the retrospective design of
our study, we were not able to assess this predictor. Coloni-
zation can only be a useful predictor if routine screening is
implemented. However, because C. difﬁcile colonization and
infection share the most important risk factors [26], we expect
the added value to be limited.
To our knowledge, three models for the prediction of CDI
risk have been previously published. The ﬁrst study examined a
risk score in patients receiving broad-spectrum antibiotics who
were admitted for at least 48 hours. Discrimination was mod-
erate, with an AUC of 0.712 in the validation cohort [16]. One
limitation of this study is that the total length of ICU stay, up to
the date of the stool test for cases and up to the discharge date
for controls, was one of the predictors in the model. Although
this is a known risk factor of CDI, prediction is warranted at a
time when length of stay is not yet known. In contrast, in our
study, we only collected data that were known at the start of in-
hospital antibiotic treatment. The second study investigated
performance of the Waterlow score in predicting CDI occur-
rence. This score is routinely used in UK hospitals to predict
the risk of acquiring decubitus ulcers, and it also appeared tofectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 786.e1–786.e8
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was performed in a cohort with only 20 cases of CDI, results
should be interpreted with caution. The third study used
electronically available data and included a measure for CDI
pressure. The model has an AUC of 0.88 [15]. As mentioned by
the authors, electronic information sources are prone to be
too institution speciﬁc, thus limiting generalizability. Further-
more, the last two risk scores have not been evaluated in a
population restricted to patients receiving systemic antibiotics.
Because this is known to be the most important factor in the
pathogenesis of CDI, validation of CDI risk prediction models in
a population of patients receiving systemic antibiotic treatment
is desirable. Recently, a fourth prognostic model has been
published [27]. However, development of diarrhoea during the
admission was one of the predictors, and the model should
therefore be considered diagnostic.
Several limitations of our study need to be addressed. We
assumed that patients did not have CDI when they were not
tested. Although it is common practice to test for CDI in pa-
tients with antibiotic-associated hospital-acquired diarrhoea,
testing may have been omitted in patients with mild or
nonspeciﬁc symptoms. Additionally, the sensitivity of the toxin
test is limited, although the interpretation of a positive nucleic
acid ampliﬁcation test and negative toxin test is also debated
[28]. As a result, we may have missed CDI cases, especially the
less severe, which may have caused over- or underestimation of
the model performance. Also, because we based the deﬁnition
of CDI mainly on a positive toxin test, some cases may have
been falsely positive. However, in our hospitals, the Clostridium
toxin test is only performed when infectious diarrhoea is sus-
pected, and we therefore assume the number of false-positive
results will be limited. Differences in diagnostic tests used in
the hospitals will have a limited effect, given that only two
additional cases were identiﬁed with PCR in the validation
cohort. Yet as the diagnostic algorithm used in the validation
hospital is more compatible with the European guideline on
diagnosing CDI [29], differences will be in favour of the vali-
dation study, which showed similar model performance
compared to the derivation study. This suggests that the dif-
ferences in diagnostic algorithms, as they were present, did not
affect the results of the model to a large degree. Nevertheless,
prospective evaluation of the risk score using a combination of
sensitive C. difﬁcile detection methods and objective clinical
criteria of CDI may be necessary.
We have excluded a substantial part of CDI cases in our
derivation cohort. Most of these cases were excluded because
the participants were already suspected of having CDI at
admission and tested positive within 48 hours. Prediction is
irrelevant if the outcome is already present, and inclusion of
these patients would have biased the results. This was mostClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectfrequent in the derivation cohort, probably because of the
tertiary care setting. In the derivation cohort, we also excluded
subsequent CDI episodes within the same patient. Including
multiple episodes that occur in the same patient might result in
more homogeneous data within the cases, which in turn could
lead to overestimation of the predictor effects. Last of all, a
number of CDI patients in the derivation cohort were excluded
because they did not receive antibiotics during the admission
and therefore were not part of our study domain. Most of these
patients received chemotherapy (data not shown), which is a
known factor predisposing to CDI infection. Validation of the
model in this patient group may be warranted in future
investigations.
Because this is a retrospective study, information bias may
have occurred. Having a history of CDI is prone to bias because
physicians may be more inclined to report this in patients with a
current episode of CDI. On the other hand, it is not surprising
that history of CDI is a strong predictor because these are
susceptible patients, and CDI is associated with high recurrence
rates [30]. For other variables in the model, information bias is
expected to be limited. A known aetiologic factor that was not
signiﬁcant in our derivation study is use of gastric acid sup-
pressants. The difference in gastric acid use between cases and
controls was relatively low in our derivation cohort, which may
explain this ﬁnding.
In conclusion, we developed and validated a model to predict
the occurrence of CDI in hospitalized patients who receive
systemic antibiotic treatment. The model showed good
discrimination, which was maintained in external validation. If
preventive interventions have a negative cost–beneﬁt balance
in the entire population, the risk prediction score could be a
valuable tool to select a population at increased risk of CDI.
Future research could compare different CDI control strate-
gies— for example, discontinuation of gastric acid suppressants,
use of probiotics or discouragement of broad-spectrum anti-
biotics, including risk stratiﬁcation and restriction of the
intervention to high-risk populations.Transparency declarationAll authors report no conﬂicts of interest relevant to this
article.References[1] Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and
mortality associated with nosocomial diarrhea due to Clostridium difﬁ-
cile. Clin Infect Dis 2002;34:346–53.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 786.e1–786.e8
CMI van Werkhoven et al. Predicting the risk of C. difﬁcile infection 786.e8[2] Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difﬁcile–
related mortality rates, United States, 1999–2004. Emerg Infect Dis
2007;13:1417–9.
[3] O’Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious
challenge of Clostridium difﬁcile–associated disease in Massachusetts
hospitals: clinical and economic consequences. Infect Control Hosp
Epidemiol 2007;28:1219–27.
[4] Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short-
and long-term attributable costs of Clostridium difﬁcile–associated dis-
ease in nonsurgical inpatients. Clin Infect Dis 2008;46:497–504.
[5] Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ.
Clostridium difﬁcile–associated disease in a setting of endemicity: iden-
tiﬁcation of novel risk factors. Clin Infect Dis 2007;45:1543–9.
[6] Howitt JR, Grace JW, Schaefer MG, Dolder C, Cannella C,
Schaefer RS. Clostridium difﬁcile–positive stools: a retrospective iden-
tiﬁcation of risk factors. Am J Infect Control 2008;36:488–91.
[7] Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM.
Incidence of and risk factors for community-associated Clostridium
difﬁcile infection: a nested case–control study. BMC Infect Dis 2011;11:
194.
[8] Owens Jr RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimi-
crobial-associated risk factors for Clostridium difﬁcile infection. Clin
Infect Dis 2008;46(Suppl. 1):S19–31.
[9] Aldeyab MA, Kearney MP, Scott MG, et al. An evaluation of the impact
of antibiotic stewardship on reducing the use of high-risk antibiotics
and its effect on the incidence of Clostridium difﬁcile infection in hospital
settings. J Antimicrob Chemother 2012;67:2988–96.
[10] Feazel LM, Malhotra A, Perencevich EN, Kaboli P, Diekema DJ,
Schweizer ML. Effect of antibiotic stewardship programmes on Clos-
tridium difﬁcile incidence: a systematic review and meta-analysis.
J Antimicrob Chemother 2014;69:1748–54.
[11] Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention
of Clostridium difﬁcile–associated diarrhea in adults and children.
Cochrane Database Syst Rev 2013;5:CD006095.
[12] Rebmann T, Carrico RM, Association for Professionals in Infection
Control and Epidemiology. Preventing Clostridium difﬁcile infections: an
executive summary of the Association for Professionals in Infection
Control and Epidemiology’s elimination guide. Am J Infect Control
2011;39:239–42.
[13] Talpaert MJ, Gopal RG, Cooper BS, Wade P. Impact of guidelines and
enhanced antibiotic stewardship on reducing broad-spectrum antibi-
otic usage and its effect on incidence of Clostridium difﬁcile infection.
J Antimicrob Chemother 2011;66:2168–74.
[14] Vonberg RP, Kuijper EJ, Wilcox MH, et al. Infection control measures
to limit the spread of. Clostridium difﬁcile Clin Microbiol Infect
2008;14(Suppl. 5):2–20.
[15] Dubberke ER, Yan Y, Reske KA, et al. Development and validation of a
Clostridium difﬁcile infection risk prediction model. Infect Control Hosp
Epidemiol 2011;32:360–6.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and In[16] Garey KW, Dao-Tran TK, Jiang ZD, Price MP, Gentry LO, Dupont HL.
A clinical risk index for Clostridium difﬁcile infection in hospitalised
patients receiving broad-spectrum antibiotics. J Hosp Infect 2008;70:
142–7.
[17] Tanner J, Khan D, Anthony D, Paton J. Waterlow score to predict
patients at risk of developing Clostridium difﬁcile–associated disease.
J Hosp Infect 2009;71:239–44.
[18] Nguyen NQ, Ching K, Fraser RJ, Chapman MJ, Holloway RH. Risk of
Clostridium difﬁcile diarrhoea in critically ill patients treated with
erythromycin-based prokinetic therapy for feed intolerance. Intensive
Care Med 2008;34:169–73.
[19] ten Berg MJ, Huisman A, van den Bemt PM, Schobben AF, Egberts AC,
van Solinge WW. Linking laboratory and medication data: new op-
portunities for pharmacoepidemiological research. Clin Chem Lab
Med 2007;45:13–9.
[20] McCabe WR, Jackson GG. Gram-negative bacteremia: etiology and
ecology. Arch Intern Med 1962;110:847–55.
[21] Huang Y, Pepe MS. Assessing risk prediction models in case–control
studies using semiparametric and nonparametric methods. Stat Med
2010;29:1391–410.
[22] Core Team R. R: a language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing; 2012.
[23] Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and
prognostic research: developing a prognostic model. BMJ 2009;338:
b604.
[24] Bruns AH, Oosterheert JJ, Kuijper EJ, et al. Impact of different
empirical antibiotic treatment regimens for community-acquired
pneumonia on the emergence of Clostridium difﬁcile. J Antimicrob
Chemother 2010;65:2464–71.
[25] Goorhuis A, van Dissel JT, Kuijper EJ. Novel risk factors for Clostridium
difﬁcile–associated disease in a setting of endemicity? Clin Infect Dis
2008;47:429–30.
[26] Hung YP, Lee JC, Lin HJ, et al. Clinical impact of Clostridium difﬁcile
colonization. J Microbiol Immunol Infect 2014. http://dx.doi.org/10.
1016/j.jmii.2014.04.011.
[27] Chandra S, Thapa R, Marur S, Jani N. Validation of a clinical prediction
scale for hospital-onset Clostridium difﬁcile infection. J Clin Gastro-
enterol 2014;48:419–22.
[28] Humphries RM, Uslan DZ, Rubin Z. Performance of Clostridium difﬁcile
toxin enzyme immunoassay and nucleic acid ampliﬁcation tests strat-
iﬁed by patient disease severity. J Clin Microbiol 2013;51:869–73.
[29] Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society
of Clinical Microbiology and Infectious Diseases (ESCMID): data re-
view and recommendations for diagnosing Clostridium difﬁcile– infection
(CDI). Clin Microbiol Infect 2009;15:1053–66.
[30] Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, FalagasME.
Treatment failure and recurrence of Clostridium difﬁcile infection
following treatment with vancomycin or metronidazole: a systematic
review of the evidence. Int J Antimicrob Agents 2012;40:1–8.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 786.e1–786.e8
